Across
- 1. In the TITAN trial no difference was seen in terms of PFS, RR or time to ... detoriation
- 3. In the pivotal trials treatment duration in 2L was not predetermined but was depending on ... and disease control
- 5. In the HORG trial 20% of the NSCLC were ... carcinoma
- 7. In the TAILOR trial the OS HR is at the limit of significance and was adjusted based on other variables than predefined in the protocol and only defined ...., while using a discutable model of multivariable analysis
Down
- 2. The principal objective of the TITAN trial was to prove superiority of erlotinib in terms of ...
- 4. In the meta-analysis of ... et al, the authors concluded that treatment with CT resulted in a better/longer PFS and RR, but not in a gain in terms of OS vs erlotinib
- 6. It was confirmed that a ... mutation predicts the absence of a response to a TKI
